CLYM
Climb Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.80
+11.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -14.0%
- EBIT
- -14.9%
- EPS
- -18.6%
- Free cash flow
- -33.6%
- Operating cash flow
- -32.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -13.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -96.8%
- EBIT
- +17.2%
- Net income
- +19.0%
- EPS
- +42.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026